DOCSLIB.ORG

The Chemically-Modified Tetracycline COL-3 and Its Parent Compound

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Chemically-Modified Tetracycline COL-3 and Its Parent Compound cells Article The Chemically-Modified Tetracycline COL-3 and Its Parent Compound Doxycycline Prevent Microglial Inflammatory Responses by Reducing Glucose-Mediated Oxidative Stress Nilson Carlos Ferreira Junior 1,2,3, Maurício dos Santos Pereira 1,2,3 , Nour Francis 1, Paola Ramirez 1, Paula Martorell 1, Florencia González-Lizarraga 4, Bruno Figadère 5, Rosana Chehin 4, Elaine Del Bel 2,3, Rita Raisman-Vozari 1,* and Patrick Pierre Michel 1,* 1 Sorbonne Université, Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, 75013 Paris, France; [email protected] (N.C.F.J.); [email protected] (M.d.S.P.); [email protected] (N.F.); [email protected] (P.R.); [email protected] (P.M.) 2 Department of Basic and Oral Biology, FORP, Campus USP, University of São Paulo, Av. Café, s/no, Ribeirão Preto 14040-904, Brazil; [email protected] 3 USP, Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), São Paulo 05508-220, Brazil 4 Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA) (CONICET-UNT-SIPROSA), CP 4000 Tucumán, Argentina; mfl[email protected] (F.G.-L.); [email protected] (R.C.) Citation: Ferreira Junior, N.C.; dos 5 BioCIS, CNRS, Université Paris-Saclay, 92290 Châtenay-Malabry, France; [email protected] Santos Pereira, M.; Francis, N.; * Correspondence: [email protected] (R.R.-V.); [email protected] (P.P.M.); Ramirez, P.; Martorell, P.; Tel.: +33-(0)157274550 (R.R.-V.); +33-(0)157274534 (P.P.M.) González-Lizarraga, F.; Figadère, B.; Chehin, R.; Del Bel, E.; Abstract: We used mouse microglial cells in culture activated by lipopolysaccharide (LPS) or α- Raisman-Vozari, R.; et al. The synuclein amyloid aggregates (αSa) to study the anti-inflammatory effects of COL-3, a tetracycline Chemically-Modified Tetracycline derivative without antimicrobial activity. Under LPS or αSa stimulation, COL-3 (10, 20 µM) efficiently COL-3 and Its Parent Compound repressed the induction of the microglial activation marker protein Iba-1 and the stimulated-release Doxycycline Prevent Microglial of the pro-inflammatory cytokine TNF-α. COL-30s inhibitory effects on TNF-α were reproduced Inflammatory Responses by by the tetracycline antibiotic doxycycline (DOX; 50 µM), the glucocorticoid dexamethasone, and Reducing Glucose-Mediated apocynin (APO), an inhibitor of the superoxide-producing enzyme NADPH oxidase. This last Oxidative Stress. Cells 2021, 10, 2163. observation suggested that COL-3 and DOX might also operate themselves by restraining oxidative https://doi.org/10.3390/ stress-mediated signaling events. Quantitative measurement of intracellular reactive oxygen species cells10082163 (ROS) levels revealed that COL-3 and DOX were indeed as effective as APO in reducing oxidative Academic Editor: Dominique Debanne stress and TNF-α release in activated microglia. ROS inhibition with COL-3 or DOX occurred together with a reduction of microglial glucose accumulation and NADPH synthesis. This suggested that Received: 29 June 2021 COL-3 and DOX might reduce microglial oxidative burst activity by limiting the glucose-dependent Accepted: 13 August 2021 synthesis of NADPH, the requisite substrate for NADPH oxidase. Coherent with this possibility, Published: 22 August 2021 the glycolysis inhibitor 2-deoxy-D-glucose reproduced the immunosuppressive action of COL-3 and DOX in activated microglia. Overall, we propose that COL-3 and its parent compound DOX Publisher’s Note: MDPI stays neutral exert anti-inflammatory effects in microglial cells by inhibiting glucose-dependent ROS production. with regard to jurisdictional claims in These effects might be strengthened by the intrinsic antioxidant properties of DOX and COL-3 in published maps and institutional affil- a self-reinforcing manner. iations. Keywords: COL-3; glucose metabolism; microglia; NADPH oxidase; neuroinflammation; oxidative stress; tetracyclines Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article 1. Introduction distributed under the terms and Tetracyclines are a family of antibiotics that inhibit bacterial protein synthesis by conditions of the Creative Commons Attribution (CC BY) license (https:// attaching to the ribosomal subunit and consequently blocking the binding of aminoacyl- creativecommons.org/licenses/by/ tRNAs to the ribosome A site [1]. Although the effects of tetracyclines as antibiotics have 4.0/). long been known, there has been a renewed interest in this family of molecules. Indeed, in Cells 2021, 10, 2163. https://doi.org/10.3390/cells10082163 https://www.mdpi.com/journal/cells Cells 2021, 10, x FOR PEER REVIEW 2 of 16 1. Introduction Tetracyclines are a family of antibiotics that inhibit bacterial protein synthesis by at- taching to the ribosomal subunit and consequently blocking the binding of aminoacyl- Cells 2021, 10, 2163 tRNAs to the ribosome A site [1]. Although the effects of tetracyclines as antibiotics have2 of 16 long been known, there has been a renewed interest in this family of molecules. Indeed, in addition to their antibacterial activity, they can exert pharmacological effects that may have clinical applications in various disease states, including cancer [2], inflammation- relatedaddition disorders to their antibacterial[3], and CNS activity, neurodegenerative they can exert pathologies pharmacological [4,5]. effects that may have clinicalAs an applications illustration in of various that, doxycycline disease states, (DOX), including an old cancertetracycline [2], inflammation-related antibiotic currently disorders [3], and CNS neurodegenerative pathologies [4,5]. used for the treatment of skin problems [6], combines anti-tumoral [7], anti-inflammatory As an illustration of that, doxycycline (DOX), an old tetracycline antibiotic currently [8], and neuroprotective [9,10] activities. In particular, a number of studies reported neu- used for the treatment of skin problems [6], combines anti-tumoral [7], anti-inflammatory [8], roprotective effects of DOX in toxin-induced animal models of Parkinson’s disease (PD) and neuroprotective [9,10] activities. In particular, a number of studies reported neuropro- [9,10]. DOX was also found to decrease the expression of several inflammation markers in tective effects of DOX in toxin-induced animal models of Parkinson’s disease (PD) [9,10]. microglial cultures activated with the bacterial inflammogen lipopolysaccharide (LPS) [8], DOX was also found to decrease the expression of several inflammation markers in mi- which indicates that DOX’s neuroprotective effects may be due in part to its ability to limit croglial cultures activated with the bacterial inflammogen lipopolysaccharide (LPS) [8], inflammation-related events [9,10]. The anti-inflammatory properties of DOX may also which indicates that DOX’s neuroprotective effects may be due in part to its ability to explain why this tetracycline provided relief against L-DOPA-induced dyskinesia in a PD limit inflammation-related events [9,10]. The anti-inflammatory properties of DOX may rat model [11]. Interestingly, DOX was also found capable of preventing amyloid aggre- also explain why this tetracycline provided relief against L-DOPA-induced dyskinesia in gation of α Synuclein (αS) and tau, two seeding-prone proteins involved in PD [12,13] and a PD rat model [11]. Interestingly, DOX was also found capable of preventing amyloid Alzheimer’saggregation ofdiseaseα Synuclein [14] pathologies, (αS) and tau, respectively, two seeding-prone suggesting proteins that involvedthis tetracycline in PD [12 has,13] theand potential Alzheimer’s of a multimod disease [14al] pathologies,neuroprotective respectively, drug. suggesting that this tetracycline has the potentialCOL-3, also of a multimodalnamed chemically neuroprotective modified drug. tetracycline 3 (CMT-3), 4-dedimethyla- minosancyclineCOL-3, also, or named incyclinide chemically, belongs modified to a group tetracycline of modified 3 (CMT-3), tetracyclines 4-dedimethylamin- that have beenosancycline, structurally or incyclinide, rearranged to belongs suppress to atheir group antibacterial of modified properti tetracyclineses. Removal that haveof the been an- timicrobialstructurally activity rearranged obtained to suppress by eliminating their antibacterial the dimethylamino properties. group Removal from of carbon the antimi- 4 in thecrobial A ring activity of the obtainedtetracycline by eliminatingcore structure the (Figure dimethylamino 1) was carried group out from with carbon the principle 4 in the ofA preserving ring of the other tetracycline activities core of structureinterest [15,16]. (Figure COL1) was-3 has carried been outtested with in theclinical principle trials ofin cancerpreserving patients other [17,18], activities and its of interestcapacity [of15 ,inhibiting16]. COL-3 matrix has been metalloproteinases tested in clinical offers trials the in possibilitycancer patients to reduce [17,18 the], and excessive its capacity breakdown of inhibiting of connective matrix metalloproteinasestissue in many pathological offers the conditionspossibility [19 to– reduce21]. COL the-3 excessive is highly breakdownlipophilic, so of it connective can cross the tissue blood in many–brain pathologicalbarrier and exertconditions CNS effects [19–21 [3,22].]. COL-3 In isthat highly respect, lipophilic, systemic so administration it can cross the of blood–brain COL-3 was barrier reported and toexert inhibit CNS brain effects microglial [3,22].
Load more

Recommended publications
  • Elevated Hydrogen Peroxide and Decreased Catalase and Glutathione
    Sullivan-Gunn and Lewandowski BMC Geriatrics 2013, 13:104 http://www.biomedcentral.com/1471-2318/13/104 RESEARCH ARTICLE Open Access Elevated hydrogen peroxide and decreased catalase and glutathione peroxidase protection are associated with aging sarcopenia Melanie J Sullivan-Gunn1 and Paul A Lewandowski2* Abstract Background: Sarcopenia is the progressive loss of skeletal muscle that contributes to the decline in physical function during aging. A higher level of oxidative stress has been implicated in aging sarcopenia. The current study aims to determine if the higher level of oxidative stress is a result of increased superoxide (O2‾ ) production by the NADPH oxidase (NOX) enzyme or decrease in endogenous antioxidant enzyme protection. Methods: Female Balb/c mice were assigned to 4 age groups; 6, 12, 18 and 24 months. Body weight and animal survival rates were recorded over the course of the study. Skeletal muscle tissues were collected and used to measure NOX subunit mRNA, O2‾ levels and antioxidant enzymes. Results: Key subunit components of NOX expression were elevated in skeletal muscle at 18 months, when sarcopenia was first evident. Increased superoxide dismutase 1 (SOD1) activity suggests an increase in O2‾ dismutation and this was further supported by elevated levels of hydrogen peroxide (H2O2) and decline in catalase and glutathione peroxidase (GPx) antioxidant protection in skeletal muscle at this time. NOX expression was also higher in skeletal muscle at 24 months, however this was coupled with elevated levels of O2‾ and a decline in SOD1 activity, compared to 6 and 12 months but was not associated with further loss of muscle mass.
    [Show full text]
  • Erythromycin Versus Tetracycline for Treatment of Mediterranean Spotted Fever
    Arch Dis Child: first published as 10.1136/adc.61.10.1027 on 1 October 1986. Downloaded from Archives of Disease in Childhood, 1986, 61, 1027-1029 Erythromycin versus tetracycline for treatment of Mediterranean spotted fever T MUNOZ-ESPIN, P LOPEZ-PARtS, E ESPEJO-ARENAS, B FONT-CREUS, I MARTINEZ- VILA, J TRAVERIA-CASANOVA, F SEGURA-PORTA, AND F BELLA-CUETO Hospital de Sant Llatzer, Terrassa, Clinica Infantil del Nen Jesus, Sabadell, and Hospital Mare de Deu de la Salut, Sabadell, Barcelona, Spain SUMMARY Eighty one children aged between 1 and 13 years participated in a randomised comparative trial of tetracycline hydrochloride and erythromycin stearate for treatment of Mediterranean spotted fever. Both therapeutic regimens proved effective, but in patients treated with tetracycline both clinical symptoms and fever disappeared significantly more quickly. Likewise, when those patients who began treatment within the first 72 hours of illness are considered the febrile period had a significantly shorter duration in the group treated with tetracycline. One patient was switched to tetracycline because there was no improvement of clinical manifestations, with persistence of fever, myalgias, and prostration, after receiving eight days of treatment with erythromycin. These results suggest that tetracyclines are superior to erythromycin in the treatment of Mediterranean spotted fever. copyright. Mediterranean spotted fever is an acute infectious were not included in the trial; neither were those disease caused by Rickettsia conorii. During the
    [Show full text]
  • Use of Antibiotics to Prevent Calf Diarrhea and Septiceinia
    PEER REVIEWED Use of Antibiotics to Prevent Calf Diarrhea and Septiceinia Peter D. Constable, BVSc, PhD, DACVIM Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802 Abstract l'oxytetracycline (0.15 to 6.0 mg/lb [0.32 to 13.2 mg/kg] au 24 h, per os) sont efficaces dans le traitement de la This article reviews studies related to the use of diarrhee chez les veaux et permettent un accroissement antimicrobial agents to prevent calf diarrhea and septi­ du taux de croissance des veaux nourris au lait. De cemia, and discusses whether prophylactic administra­ plus, la chlortetracycline permet la diminution du taux tion of antibiotics in neonatal calves is effective and de mortalite lorsque administree chez les veaux indicated. Orally administered chlortetracycline, oxytet­ nouveau-nes pour prevenir la diarrhee. 11 n'y a pas racycline, tetracycline and neomycin have label claims d'antibiotiques qui promettent de prevenir la in the US for the "control" or "aid in the control" of calf septicemie chez les veaux. Paree qu'il ne semble pas diarrhea caused by bacteria susceptible to the antibi­ exister d'etudes sur l'efficacite de la tetracycline et de otic. Chlortetracycline and oxytetracycline (0.15 to 6.0 la neomycine et parce que !'utilisation hors homologa­ mg/lb [0.32 to 13.2 mg/kg], q 24 h, PO) are efficacious tion des medicaments. n'est pas permise pour la for preventing calf diarrhea and increasing growth rate prevention routiniere des maladies ou !'augmentation in milk-fed calves, and chlortetracycline (3 mg/lb [7 mg/ du taux de croissance et du taux de conversion kg], q 12 h, PO) is efficacious for decreasing mortality alimentaire, selon le code de l'AMDUCA de 1994, seule when administered to prevent diarrhea in neonatal !'administration orale de chlortetracycline et calves.
    [Show full text]
  • ARS-2014-6136-Ver9-Huang 6P 973..984
    ANTIOXIDANTS & REDOX SIGNALING Volume 23, Number 12, 2015 DOI: 10.1089/ars.2014.6136 ORIGINAL RESEARCH COMMUNICATION Redox Regulation of Pro-IL-1b Processing May Contribute to the Increased Severity of Serum-Induced Arthritis in NOX2-Deficient Mice Ya-Fang Huang,1 Pei-Chi Lo,1 Chia-Liang Yen,2 Peter Andrija Nigrovic,3,4 Wen-Chen Chao,1,5 Wei-Zhi Wang,1 George Chengkang Hsu,1 Yau-Sheng Tsai,1 and Chi-Chang Shieh1,6 Abstract Aims: To elucidate the role of reactive oxygen species (ROS) in arthritis and to identify targets of arthritis treatment in conditions with different levels of oxidant stress. Results: Through establishing an arthritis model by injecting arthritogenic serum into wild-type and NADPH oxidase 2 (NOX2)-deficient mice, we found that arthritis had a neutrophilic infiltrate and was more severe in Ncf1 - / - mice, a mouse strain lacking the expression of the NCF1/p47phox component of NOX2. The levels of interleukin-1b (IL-1b) and IL-6 in inflamed joints were higher in Ncf1 - / - than in controls. Antagonists of tumor necrosis factor-a (TNFa) and IL-1b were equally effective in suppressing arthritis in wild-type mice, while IL-1b blockade was more effective than TNFa blockade in Ncf1 - / - mice. A treatment of caspase inhibitor and the combination treatment of a caspase inhibitor and a cathepsin inhibitor, but not a cathepsin inhibitor alone, suppressed arthritic severity in the wild-type mice, while a treatment of cathepsin inhibitor and the combination treatment of a caspase inhibitor and a cathepsin inhibitor, but not a caspase inhibitor alone, were effective in treating Ncf1 - / - mice.
    [Show full text]
  • Cytochrome P450 Enzymes but Not NADPH Oxidases Are the Source of the MARK NADPH-Dependent Lucigenin Chemiluminescence in Membrane Assays
    Free Radical Biology and Medicine 102 (2017) 57–66 Contents lists available at ScienceDirect Free Radical Biology and Medicine journal homepage: www.elsevier.com/locate/freeradbiomed Cytochrome P450 enzymes but not NADPH oxidases are the source of the MARK NADPH-dependent lucigenin chemiluminescence in membrane assays Flávia Rezendea, Kim-Kristin Priora, Oliver Löwea, Ilka Wittigb, Valentina Streckerb, Franziska Molla, Valeska Helfingera, Frank Schnütgenc, Nina Kurrlec, Frank Wempec, Maria Waltera, Sven Zukunftd, Bert Luckd, Ingrid Flemingd, Norbert Weissmanne, ⁎ ⁎ Ralf P. Brandesa, , Katrin Schrödera, a Institute for Cardiovascular Physiology, Goethe-University, Frankfurt, Germany b Functional Proteomics, SFB 815 Core Unit, Goethe-Universität, Frankfurt, Germany c Institute for Molecular Hematology, Goethe-University, Frankfurt, Germany d Institute for Vascular Signaling, Goethe-University, Frankfurt, Germany e University of Giessen, Lung Center, Giessen, Germany ARTICLE INFO ABSTRACT Keywords: Measuring NADPH oxidase (Nox)-derived reactive oxygen species (ROS) in living tissues and cells is a constant NADPH oxidase challenge. All probes available display limitations regarding sensitivity, specificity or demand highly specialized Nox detection techniques. In search for a presumably easy, versatile, sensitive and specific technique, numerous Lucigenin studies have used NADPH-stimulated assays in membrane fractions which have been suggested to reflect Nox Chemiluminescence activity. However, we previously found an unaltered activity with these assays in triple Nox knockout mouse Superoxide (Nox1-Nox2-Nox4-/-) tissue and cells compared to wild type. Moreover, the high ROS production of intact cells Reactive oxygen species Membrane assays overexpressing Nox enzymes could not be recapitulated in NADPH-stimulated membrane assays. Thus, the signal obtained in these assays has to derive from a source other than NADPH oxidases.
    [Show full text]
  • Long-Term Use of Spironolactone for Acne in Women: a Case Series of 403 Patients
    Long-term use of spironolactone for acne in women: A case series of 403 patients Vaibhav Garg, BS,a JulianaK.Choi,MD,PhD,b William D. James, MD,b and John S. Barbieri, MD, MBAb Philadelphia, Pennsylvania Background: There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. Objective: To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. Methods: We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use. Results: As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50). Limitations: This study was conducted at a single academic medical center. Conclusions: Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration. ( J Am Acad Dermatol 2021;84:1348-55.) Key words: acne; acne vulgaris; birth control pill; combined oral contraceptive; comprehensive acne severity scale; oral antibiotics; outcomes; spironolactone.
    [Show full text]
  • Prednisolone / Neomycin / Tetracycline For- Mulation
    SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 25.08.2020 3.6 09.04.2021 407521-00015 Date of first issue: 07.01.2016 SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1 Product identifier Trade name : Prednisolone / Neomycin / Tetracycline Formulation 1.2 Relevant identified uses of the substance or mixture and uses advised against Use of the Sub- : Veterinary product stance/Mixture 1.3 Details of the supplier of the safety data sheet Company : MSD 20 Spartan Road 1619 Spartan, South Africa Telephone : +27119239300 E-mail address of person : [email protected] responsible for the SDS 1.4 Emergency telephone number +1-908-423-6000 SECTION 2: Hazards identification 2.1 Classification of the substance or mixture Classification (REGULATION (EC) No 1272/2008) Skin sensitisation, Category 1 H317: May cause an allergic skin reaction. Reproductive toxicity, Category 1A H360D: May damage the unborn child. Effects on or via lactation H362: May cause harm to breast-fed children. Short-term (acute) aquatic hazard, Cate- H400: Very toxic to aquatic life. gory 1 Long-term (chronic) aquatic hazard, Cat- H410: Very toxic to aquatic life with long lasting egory 1 effects. 2.2 Label elements Labelling (REGULATION (EC) No 1272/2008) Hazard pictograms : Signal word : Danger Hazard statements : H317 May cause an allergic skin reaction. H360D May damage the unborn child. H362 May cause harm to breast-fed children. H410 Very toxic to aquatic life with long lasting effects. 1 / 23 SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 25.08.2020 3.6 09.04.2021 407521-00015 Date of first issue: 07.01.2016 Precautionary statements : Prevention: P201 Obtain special instructions before use.
    [Show full text]
  • Staining and Hypoplasia of Enamel Caused by Tetracycline: Case Report P
    PEDIATRIC DENTISTRY/Copyright © 1987 by The American Academy of Pediatric Dentistry Volume 9 Number 3 Staining and hypoplasia of enamel caused by tetracycline: case report P. Fleming, BDentSc, FDS C.J. Witkop, Jr., DDS, MS W.H. Kuhlmann, DDS, MSD Abstract Case Report Staining of developing teeth due to tetracycline therapy A 23-year-old white male requested restoration of has been publicized widely. However, the ability of tetracy- his stained and hypoplastic anterior teeth (Fig 1). A clines to cause hypoplasia of enamel has not been accepted history revealed that between 2 and 3 years of age he had universally. This is a case report of enamel hypoplasia and received extensive tetracycline therapy for tonsillitis. staining presumably caused byahigh dosage of'tetracy'dines in There was no history of a prolonged fever at the time of childhood. Restoration of the teeth with bonded composite the illness. resins produced an esthetic result. -UK Schwachman and Schuster (1956) were the first to report unsightly staining of teeth due to tetracycline administered during the period of tooth formation in children with cystic fibrosis. This observation was con- y firmed by Zegarelli et al. (1961) who noted staining of the teeth in 38 of 52 cystic fibrosis patients who had been ijgj treated with large doses of antibiotics, frequently tetracy- .^••W^^ clines. With reports by Davies et al. (1962) and articles by Wallman and Hilton (1962) and Witkop and Wolf (1963) this complication of tetracycline therapy became widely recognized. FIG 1. Tetracycline staining and hypoplasia of the permanent Hypoplasia of enamel of the primary dentition asso- anterior teeth.
    [Show full text]
  • The Relationship of NADPH Oxidases and Heme Peroxidases: Fallin' In
    MINI REVIEW published: 05 March 2019 doi: 10.3389/fimmu.2019.00394 The Relationship of NADPH Oxidases and Heme Peroxidases: Fallin’ in and Out Gábor Sirokmány 1,2* and Miklós Geiszt 1,2* 1 Department of Physiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary, 2 “Momentum” Peroxidase Enzyme Research Group of the Semmelweis University and the Hungarian Academy of Sciences, Budapest, Hungary Peroxidase enzymes can oxidize a multitude of substrates in diverse biological processes. According to the latest phylogenetic analysis, there are four major heme peroxidase superfamilies. In this review, we focus on certain members of the cyclooxygenase-peroxidase superfamily (also labeled as animal heme peroxidases) and their connection to specific NADPH oxidase enzymes which provide H2O2 for the Edited by: Gabor Csanyi, one- and two-electron oxidation of various peroxidase substrates. The family of NADPH Augusta University, United States oxidases is a group of enzymes dedicated to the production of superoxide and hydrogen Reviewed by: peroxide. There is a handful of known and important physiological functions where Tohru Fukai, Augusta University, United States one of the seven known human NADPH oxidases plays an essential role. In most of Patrick Pagano, these functions NADPH oxidases provide H2O2 for specific heme peroxidases and University of Pittsburgh, United States the concerted action of the two enzymes is indispensable for the accomplishment *Correspondence: of the biological function. We discuss human and other metazoan examples of such Gábor Sirokmány sirokmany.gabor@ cooperation between oxidases and peroxidases and analyze the biological importance med.semmelweis-univ.hu of their functional interaction. We also review those oxidases and peroxidases where this Miklós Geiszt geiszt.miklos@ kind of partnership has not been identified yet.
    [Show full text]
  • Prednisolone / Neomycin / Tetracycline For- Mulation
    SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.5 25.08.2020 407516-00013 Date of first issue: 07.01.2016 SECTION 1. PRODUCT AND COMPANY IDENTIFICATION Product name : Prednisolone / Neomycin / Tetracycline Formulation Manufacturer or supplier's details Company name of supplier : MSD Address : 2000 Galloping Hill Road Kenilworth - New Jersey - U.S.A. 07033 Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000 E-mail address : [email protected] Recommended use of the chemical and restrictions on use Recommended use : Veterinary product SECTION 2. HAZARDS IDENTIFICATION GHS Classification Skin sensitization : Category 1 Reproductive toxicity : Category 1A Effects on or via lactation Specific target organ toxicity : Category 2 (Kidney, inner ear) - repeated exposure Specific target organ toxicity : Category 2 (Gastrointestinal tract, Nervous system, Skin, Teeth) - repeated exposure (Oral) GHS label elements Hazard pictograms : Signal Word : Danger Hazard Statements : H317 May cause an allergic skin reaction. H360D May damage the unborn child. H362 May cause harm to breast-fed children. H373 May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure. H373 May cause damage to organs (Gastrointestinal tract, Nervous system, Skin, Teeth) through prolonged or repeated exposure if swallowed. Precautionary Statements : Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. 1 / 24 SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.5 25.08.2020 407516-00013 Date of first issue: 07.01.2016 P260 Do not breathe dust.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Role of NADPH Oxidase in Arsenic-Induced Reactive Oxygen Species Formation and Cytotoxicity in Myeloid Leukemia Cells
    Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells Wen-Chien Chou*†‡, Chunfa Jie§, Andrew A. Kenedy¶, Richard J. Jonesʈ, Michael A. Trush¶, and Chi V. Dang*†¶ʈ** *Program of Human Genetics and Molecular Biology, †Department of Medicine, §McKusick–Nathans Institute of Genetic Medicine, and ʈSidney Kimmel Comprehensive Cancer Center, School of Medicine, ¶Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205 Edited by Owen N. Witte, University of California, Los Angeles, CA, and approved January 21, 2004 (received for review October 16, 2003) Arsenic has played a key medicinal role against a variety of associated and cytosolic subunits, can be stimulated by phorbol ailments for several millennia, but during the past century its myristate acetate (PMA) through protein kinase C-mediated prominence has been displaced by modern therapeutics. Recently, phosphorylation of the p47PHOX subunit (17, 18). This complex attention has been drawn to arsenic by its dramatic clinical efficacy is responsible for the production of superoxide anion (respira- against acute promyelocytic leukemia. Although toxic reactive tory burst) of professional phagocytes encountering microbial oxygen species (ROS) induced in cancer cells exposed to arsenic pathogens, and its importance in host immunity is underscored could mediate cancer cell death, how arsenic induces ROS remains by the immunocompromised congenital disease, chronic gran- undefined. Through the use of gene expression profiling, interfer- ulomatous disease (CGD), which results from mutations in one ence RNA, and genetically engineered cells, we report here that of the subunits of NADPH oxidase (19, 20).
    [Show full text]